A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Clinical trial NCT06732323 · RECRUITING

Trial details

NCT number: NCT06732323
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Triple-Negative Breast Cancer (TNBC)

Start date: 2025-09-04
Primary completion: 2027-06-01
Enrollment: 504

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.